Cfo
CurrentCytoAgents is a clinical-stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. The company has successfully completed its Phase I clinical trial and will.